Call Us Today! LONDON: +44 (0)207 202 0900 | TOULOUSE +33 5 61 00 13 40|Email: fns@feedinfo.com

Dechra Pharmaceuticals’ FY Revenues Grow

“As we complete our 20th year since inception of the Company, we are pleased to report that the Group has delivered another strong financial performance.” -Ian Page, Chief Executive Officer
Highlights

Strategic progress made:

· Core portfolio growth solid in EU, excellent in NA; major therapeutic sectors continue to grow.

· Strong performance from prior year acquisitions.

· Apex (Australia) completed and integrated, and 33.0% share of Medical Ethics Pty Ltd acquired.

· New geographic territories performing well; new Dechra Veterinary Products International team to create greater focus.

· Significant pipeline delivery with two new FAP EU registrations and numerous international approvals.

· Exploring several new pipeline opportunities.

Strong financial performance:

· Strong revenue growth of 28.3% at constant exchange rates (CER).

· Solid revenue growth in Companion Animal Products (CAP), Food producing Animal Products (FAP), and Equine.

· 36.9% growth at CER in underlying operating profit.

· Strong operational leverage and full year synergies from acquisitions lifts EBIT margin 140 bps to 22.6%.

· Consistently strong cash conversion of 115.9%, driving Net Debt / underlying EBITDA leverage down from 2.0 to 1.4 times.

· Underlying diluted EPS growth of 35.1%; increase in full year dividend to 21.44 pence.

By |2017-10-10T11:42:35+00:00September 20th, 2017|